EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 7, 2006--Chiron Corporation (Nasdaq:CHIR) today announced that the staff of the Securities and Exchange Commission (SEC) has decided to terminate its investigation of whether Chiron violated any federal securities laws in connection with the previous suspension by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of Chiron’s license to manufacture FLUVIRIN(R) influenza virus vaccine and has ended its inquiry into the company’s restatement of financial results for the second and third quarters of 2004. Chiron has been informed that no enforcement action has been recommended against the company in connection with these matters.
